Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib and GSK1120212 in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer

Inclusion Criteria:

• For dose escalation cohort, patients with advanced inoperable solid tumors. For dose expansion cohort, patients with advanced, inoperable differentiated thyroid cancer (DTC) will be enrolled. Disease must be biopsiable.
• Must have measurable disease.
• Patients with DTC must have radioiodine non-avid lesions, OR with radioiodine avid lesions that have not responded to treatment with radioactive iodine.
• ECOG performance status less than or equal to 1.
• Life expectancy >3 months.
• Treated brain mets allowed if stable at least 8 weeks, off of glucocorticoids.
• Adequate organ function.
• Women of child bearing potential and must agree to use adequate contraception prior to study entry and for 3 months after study completion.
• Tumor progression in the 6-month period prior to study drug initiation.
• Blood pressure <140 mmHg and <90 mmHg.
• LVEF is >= 50%
• Must be able to swallow pills.

Exclusion Criteria:

• Chemotherapy or radiotherapy within 4 weeks.
• Pregnant or currently breastfeeding.
• Unresolved toxicity greater than grade 1.
• Evidence of active hepatitis or HIV.
• Significant cardiovascular disease.
• Taking medications known to be strong inducers or inhibitors of CYP3A enzymes.
• Use of investigation drug within 28 days of study drug start date.
• Major surgery within 4 weeks prior to study entry.
• Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding.
• History of gastrointestinal condition causing malabsorption or obstruction.
• Cerebrovascular accident including ischemic attack (TIA), pulmonary embolism or untreated deep vein thrombosis (DVT) within past 6 months.
• Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels that increase risk of pulmonary hemorrhage.
• Hemoptysis within 6 months of starting treatment.
• History of retinal vein occlusion (RVO) or central serous retinopathy (CSR), or predisposing factors to RVO or CSR as assessed by ophthalmic exam.
• Uncontrolled intercurrent illness and/or concurrent condition that, in the Investigator's opinion, would jeopardize the safety of patient or compliance with protocol.